リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Isolation of a human SARS-CoV-2 neutralizing antibody from a synthetic phage library and its conversion to fluorescent biosensors」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Isolation of a human SARS-CoV-2 neutralizing antibody from a synthetic phage library and its conversion to fluorescent biosensors

朱 博 ネイ セツジョウ 董 金華 上田 宏 東京工業大学 DOI:https://doi.org/10.1038/s41598-022-19699-z

2022.09.15

概要

Since late 2019, the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resultant spread of COVID-19 have given rise to a worldwide health crisis that is posing great challenges to public health and clinical treatment, in addition to serving as a formidable threat to the global economy. To obtain an effective tool to prevent and diagnose viral infections, we attempted to obtain human antibody fragments that can effectively neutralize viral infection and be utilized for rapid virus detection. To this end, several human monoclonal antibodies were isolated by bio-panning a phage-displayed human antibody library, Tomlinson I. The selected clones were demonstrated to bind to the S1 domain of the spike glycoprotein of SARS-CoV-2. Moreover, clone A7 in Fab and IgG formats were found to effectively neutralize the binding of S protein to angiotensin-converting enzyme 2 in the low nM range. In addition, this clone was successfully converted to quench-based fluorescent immunosensors (Quenchbodies) that allowed antigen detection within a few minutes, with the help of a handy fluorometer.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273. https://doi. org/10.1038/s41586-020-2012-7 (2020).

2. Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292. https://doi.org/ 10.1016/j.cell.2020.02.058 (2020).

3. Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibi- tor. Cell 181, 271–280. https://doi.org/10.1016/j.cell.2020.02.052 (2020).

4. Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444–1448. https://doi. org/10.1126/science.abb2762 (2020).

5. Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220. https://doi.org/10.1038/s41586-020-2180-5 (2020).

6. Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450–454. https://doi. org/10.1038/nature02145 (2003).

7. Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395, 565–574. https://doi.org/10.1016/S0140-6736(20)30251-8 (2020).

8. Drozdzal, S. et al. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist. Update 53, 100719. https://doi.org/10.1016/j.drup.2020.100719 (2020).

9. Artese, A. et al. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Drug Resist. Update 53, 100721. https://doi.org/10.1016/j.drup.2020.100721 (2020).

10. Baum, A. et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 370, 1110–1115. https://doi.org/10.1126/science.abe2402 (2020).

11. Jiang, S., Hillyer, C. & Du, L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 41, 355–359. https://doi.org/10.1016/j.it.2020.03.007 (2020).

12. Oliviero, A., de Castro, F., Coperchini, F., Chiovato, L. & Rotondi, M. COVID-19 pulmonary and olfactory dysfunctions: Is the chemokine CXCL10 the common denominator?. Neuroscientist https://doi.org/10.1177/1073858420939033 (2020).

13. Wu, Y. et al. Identification of human single-domain antibodies against SARS-CoV-2. Cell Host Microbe 27, 891–898. https://doi. org/10.1016/j.chom.2020.04.023 (2020).

14. Huo, J. et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat. Struct. Mol. Biol. 27, 846–854. https://doi.org/10.1038/s41594-020-0469-6 (2020).

15. Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682–687. https://doi. org/10.1038/s41586-020-2852-1 (2020).

16. Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010– 1014. https://doi.org/10.1126/science.abd0827 (2020).

17. Monteil, V. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181, 905–913. https://doi.org/10.1016/j.cell.2020.04.004 (2020).

18. Cardone, M., Yano, M., Rosenberg, A. S. & Puig, M. Lessons learned to date on COVID-19 hyperinflammatory syndrome: Con- siderations for interventions to mitigate SARS-CoV-2 viral infection and detrimental hyperinflammation. Front. Immunol. 11, 1131. https://doi.org/10.3389/fimmu.2020.01131 (2020).

19. Iwanaga, N. et al. Novel ACE2-IgG1 fusions with improved activity against SARS-CoV2. bioRxiv https://doi.org/10.1101/2020.06. 15.152157 (2020).

20. Abe, R. et al. “Quenchbodies”: Quench-based antibody probes that show antigen-dependent fluorescence. J. Am. Chem. Soc. 133, 17386–17394. https://doi.org/10.1021/ja205925j (2011).

21. Abe, R. et al. Ultra Q-bodies: Quench-based antibody probes that utilize dye-dye interactions with enhanced antigen-dependent fluorescence. Sci. Rep. 4, 4640. https://doi.org/10.1038/srep04640 (2014).

22. Ohashi, H. et al. Insight into the working mechanism of quenchbody: Transition of the dye around antibody variable region that fluoresces upon antigen binding. Bioconjug. Chem. 27, 2248–2253 (2016).

23. Zhao, S., Dong, J., Jeong, H. J., Okumura, K. & Ueda, H. Rapid detection of the neonicotinoid insecticide imidacloprid using a quenchbody assay. Anal. Bioanal. Chem. 410, 4219–4226. https://doi.org/10.1007/s00216-018-1074-y (2018).

24. Inoue, A., Ohmuro-Matsuyama, Y., Kitaguchi, T. & Ueda, H. Creation of a nanobody-based fluorescent immunosensor mini Q-body for rapid signal-on detection of small hapten methotrexate. ACS Sens. 5, 3457–3464. https://doi.org/10.1021/acssensors. 0c01404 (2020).

25. Dong, J., Fujita, R., Zako, T. & Ueda, H. Construction of Quenchbodies to detect and image amyloid beta oligomers. Anal. Biochem. 550, 61–67. https://doi.org/10.1016/j.ab.2018.04.016 (2018).

26. Jeong, H. J. et al. Development of a quenchbody for the detection and imaging of the cancer-related tight-junction-associated membrane protein Claudin. Anal. Chem. 89, 10783–10789. https://doi.org/10.1021/acs.analchem.7b02047 (2017).

27. Jeong, H. J., Dong, J. & Ueda, H. Single-step detection of the influenza virus hemagglutinin using bacterially-produced Quench- bodies. Sensors 19, 52. https://doi.org/10.3390/s19010052 (2018).

28. Dong, J., Oka, Y., Jeong, H. J., Ohmuro-Matsuyama, Y. & Ueda, H. Detection and destruction of HER2-positive cancer cells by Ultra Quenchbody-siRNA complex. Biotechnol. Bioeng. 117, 1259–1269. https://doi.org/10.1002/bit.27302 (2020).

29. Jeong, H. J. et al. Detection of vimentin serine phosphorylation by multicolor Quenchbodies. Biosens. Bioelectron. 40, 17–23. https://doi.org/10.1016/j.bios.2012.06.030 (2013).

30. Dong, J., Jeong, H. J. & Ueda, H. Preparation of Quenchbodies by protein transamination reaction. J. Biosci. Bioeng. 122, 125–130. https://doi.org/10.1016/j.jbiosc.2015.12.010 (2016).

31. Jeong, H. J. et al. Construction of dye-stapled Quenchbodies by photochemical crosslinking to antibody nucleotide-binding sites. Chem. Commun. (Camb.) 53, 10200–10203. https://doi.org/10.1039/c7cc03043f (2017).

32. Dong, J. et al. PM Q-probe: A fluorescent binding protein that converts many antibodies to a fluorescent biosensor. Biosens. Bio- electron. 165, 112425. https://doi.org/10.1016/j.bios.2020.112425 (2020).

33. Smith, G. P. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315–1317. https://doi.org/10.1126/science.4001944 (1985).

34. McCafferty, J., Griffiths, A. D., Winter, G. & Chiswell, D. J. Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 348, 552–554. https://doi.org/10.1038/348552a0 (1990).

35. de Wildt, R. M. T., Mundy, C. R., Gorick, B. D. & Tomlinson, I. M. Antibody arrays for high-throughput screening of antibody– antigen interactions. Nat. Biotechnol. 18, 989–994. https://doi.org/10.1038/79494 (2000).

36. Swindells, M. B. et al. abYsis: Integrated antibody sequence and structure: Management, analysis and prediction. J. Mol. Biol. 429, 356–364 (2017).

37. Parray, H. A. et al. Identification of an anti-SARS-CoV-2 receptor-binding domain-directed human monoclonal antibody from a naive semisynthetic library. J. Biol. Chem. 295, 12814–12821. https://doi.org/10.1074/jbc.AC120.014918 (2020).

38. Yuan, M. et al. Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein-ACE2 interaction. Cell Mol. Immunol. 18, 1562–1564. https://doi.org/10.1038/s41423-021-00684-x (2021).

39. Quijano-Rubio, A. et al. De novo design of modular and tunable protein biosensors. Nature 591, 482–487. https://doi.org/10.1038/ s41586-021-03258-z (2021).

40. Grant, B. D. et al. SARS-CoV-2 coronavirus nucleocapsid antigen-detecting half-strip lateral flow assay toward the development of point of care tests using commercially available reagents. Anal. Chem. 92, 11305–11309. https://doi.org/10.1021/acs.analchem. 0c01975 (2020).

41. Pollock, N. R. et al. Correlation of SARS-CoV-2 nucleocapsid antigen and RNA concentrations in nasopharyngeal samples from children and adults using an ultrasensitive and quantitative antigen assay. J. Clin. Microbiol. 59, e03077. https://doi.org/10.1128/ JCM.03077-20 (2021).

42. Shan, D. et al. N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection. Nat. Commun. 12, 1931. https://doi.org/10.1038/s41467-021-22072-9 (2021).

43. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680–685. https:// doi.org/10.1038/227680a0 (1970).

44. Pack, P., Müller, K., Zahn, R. & Plückthun, A. Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J. Mol. Biol. 246, 28–34. https://doi.org/10.1006/jmbi.1994.0062 (1995).

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る